Biometrics Specialists
Quanticate In U.S.
Quanticate is raising its U.S. profile and considering acquisitions.
Earlier this week, JNJ said it will buy the Swiss medical device firm Synthes for $21.3 billion. A debased U.S. dollar isn't worth much these days. Still, 21.3 billion of anything remains an impressively tall pile. Uniquely in big pharma, JNJ has a record of megadeals that have been years ahead of peer companies. With numerous semi-autonomous groups under its corporate umbrella, JNJ hasn't made any egregious miscalculations or gotten so big and bureaucratic that it failed to meet Wall Street expectations. As readers know, JNJ was the first big drug company to invest in both biotechnology and medical devices in major ways. So it's interesting that its executives are placing another huge bet on devices, spending a sum equal to a third of JNJ's current annual revenues. Elevated Hopes The deal elicited the usual confident statements from senior management. JNJ's existing device business and Synthes "will create the most innovative…more...
The project manager’s lot in life is not always glamorous and filled with the drama of a James Bond movie. But as with any job in any industry, the project manager’s…more...
In watching respiratory therapists recruit for two studies under way in her departments at both Mount Sinai Hospital and SickKids Hospital in Toronto, neonatologist Sharon Unger thought she saw a trend.…more...
Not all that long ago, shippers of drug supplies for clinical trials were content to know: Did our drug ship? Then they wanted to learn: Did our supplies get stuck in…more...
The drug development industry has spun its wheels for years, trying to come up with universal metrics to measure speed and efficiency. But metrics that accurately measure quality in a trial? No one has attempted that yet. Until now. The Metrics Champion Consortium (MCC), a non-profit collaborative effort of sponsors, contract research organizations (CROs) and vendors, was…more...
Wondering what the FDA's special protocol assessments (SPAs) are all about, but too afraid to ask? Last year's Drug Information Association's (DIA) 45th annual meeting was especially helpful, as representatives of Bristol-Myers Squibb, GlaxoSmithKline (GSK) and the FDA's Office of New Drugs within the Center for Drug Evaluation and Research (CDER) presented on the topic. An SPA,…more...
What's to become of the contract research organization (CRO) industry while the economy attempts to right itself? According to a recent report by Frost & Sullivan, there's good news: the CRO industry will likely keep growing. In the current climate, pharmaceutical and biotechnology companies are unlikely to invest in in-house capabilities to conduct their own clinical trials,…more...
It may not be quite as revealing as the Sports Illustrated swimsuit issue. Or as heavily mathematical as the Dow Jones Industrial Average. But the members of the 2009 ClinPage Master Providers list do have a few qualities in common. We're announcing the list today, and will have two additional stories. In aggregate, the dozen companies on…more...
Quanticate is raising its U.S. profile and considering acquisitions.
Thoughts on a potentially transformative alternative to EDC, the electronic health record (EHR).
This emerging market just got more competitive with some new, potentially exciting regulatory changes. The first in a series.
From France, a hybrid system that uses special paper and a scanner-pen to gather clinical data.
With ISO certification, a California firm tries to lower regulatory risks inherent in translation by ensuring high quality—and avoiding mistakes.
PharmaNet was downgraded from stable to negative by Standard and Poor’s, thanks to $60 million in lost contracts.
Though not widely used in industry, the systematic review could help it use resources more efficiently.
Organizations
Conferences
Info & Opinion
© 2012 ClinPage. All Rights Reserved.